Biomarkers and therapeutic targets for bladder and prostate cancer
David M Berman (Director of QCRI, Principal Investigator, and Professor of Pathology, Oncology and Biomedical & Molecular Sciences) directs a research laboratory focused on high impact cancer tests for patients with prostate and bladder cancer. Laboratory members discover and evaluate novel biomarkers and therapeutic targets that can rapidly improve the lives of patients. To do this, we integrate information from massive genomic databases, our own experimental studies, and carefully curated human biospecimens. The result is a powerful approach that uses every available type of analysis.